Low-pressure pulsed focused ultrasound with microbubbles promotes an anticancer immunological response
© Liu et al.; licensee BioMed Central Ltd. 2012
Received: 20 May 2012
Accepted: 7 November 2012
Published: 11 November 2012
High-intensity focused-ultrasound (HIFU) has been successfully employed for thermal ablation of tumors in clinical settings. Continuous- or pulsed-mode HIFU may also induce a host antitumor immune response, mainly through expansion of antigen-presenting cells in response to increased cellular debris and through increased macrophage activation/infiltration. Here we demonstrated that another form of focused ultrasound delivery, using low-pressure, pulsed-mode exposure in the presence of microbubbles (MBs), may also trigger an antitumor immunological response and inhibit tumor growth.
A total of 280 tumor-bearing animals were subjected to sonographically-guided FUS. Implanted tumors were exposed to low-pressure FUS (0.6 to 1.4 MPa) with MBs to increase the permeability of tumor microvasculature.
Tumor progression was suppressed by both 0.6 and 1.4-MPa MB-enhanced FUS exposures. We observed a transient increase in infiltration of non-T regulatory (non-Treg) tumor infiltrating lymphocytes (TILs) and continual infiltration of CD8+ cytotoxic T-lymphocytes (CTL). The ratio of CD8+/Treg increased significantly and tumor growth was inhibited.
Our findings suggest that low-pressure FUS exposure with MBs may constitute a useful tool for triggering an anticancer immune response, for potential cancer immunotherapy.
The potential use of focused ultrasound for cancer treatment has long been recognized. Continuous-wave (CW) high-intensity focused ultrasound (HIFU) is a particularly promising approach to rapidly produce high temperatures at the target site, resulting in necrosis of tumor cells [1–4]. Ultrasonic energy emitted from concave piezoelectric ceramics can be tightly focused with radial and axial dimensions of only 1–2 mm and 10–20 mm, respectively, based on the range of frequencies and transducer geometry, so multiple sonications are required to achieve complete tumor ablation [2–6]. CW-HIFU has been successfully applied for non-malignant-cancer treatment, such as partial ablation of uterine fibroids for symptomatic relief [4, 7], relief of bone-metastasis pain [8, 9], or preliminary high-precision targeted ablation in the brain [3, 10, 11]. Medical imaging can be used to guide ablation of malignant solid tumors in breast cancer [12, 13], prostate cancer , pancreatic cancer , or liver cancer [13, 15], by introduction of multiple “cigar”-shaped thermal lesions to avoid leaving any residual tumor behind.
Mounting evidence suggests that in addition to thermal ablation of cancer cells, HIFU may also boost the host antitumor immune response including CD4+/CD8+ related tumor-infiltrating lymphocytes (TILs) [16, 17], dendritic cells (DCs) , and antigen presenting cells (APCs). This effect could potentially reduce local tumor recurrence and metastasis, especially in patients with low antitumor-immunity or inaccessible tumors. In addition to direct ablation by CW-HIFU, some studies have demonstrate that pulsed-mode HIFU with negative pressures equal or higher than that used for thermal ablation (7–12 MPa) boosts the systemic antitumor immune response through activation and maturation of DCs or APCs [20, 21]. Although pulsed-HIFU and CW-HIFU rely on different cell-killing mechanisms, both induce local tumor debris which contains tumor antigens or heat-shock proteins that could directly or indirectly enhance the infiltration of DCs .
Recent reports suggest that the permeability of blood vessels can be greatly increased by focused ultrasound in the presence of microbubbles (MB). These MBs can be used to enhance targeted delivery of chemotherapeutic agents, even at greatly reduced acoustic pressures only slightly above the pressure threshold employed in diagnostic ultrasound [23–25]. The enhanced permeability could conceivably also result in boosting the antitumor immune response by altering the tumor microenvironment, enhancing chemokine/cytokine release from tumor cells, or increasing infiltration of immune cells such as tumor-infiltrating lymphocytes (TILs) . Currently little is known about a potential antitumor immune response upon treatment with low-pressure FUS and MBs.
Here we investigated the immunological changes induced by MB-enhanced, low-pressure FUS using a CT-26 tumor murine model. We found that pulse-mode low-pressure FUS exposure in the presence of MBs (denoted as MB-FUS) could trigger a significant anticancer immune response and significantly suppressed tumor progression.
Mouse subcutaneous tumor model
BALB/c mice purchased from the the National Laboratory Animal Center were bred in the animal house of Chang Gung University and were used in experiments at age 8–10 weeks. A total of 280 animals were used in this study. All animal experiments were approved by the Animal Committee and conformed to the experimental animal care guidelines (IACUC Approval No. CGU11-058; Chang-Gung University, Taoyuan, Taiwan). CT26 cells were cultured at 37°C in a humidified 5% CO2 atmosphere in RPMI1640 medium (GIBCO, CA, USA) containing 0.25% D-glucose, 0.15% sodium bicarbonate, 10 mM HEPES, 10 mM sodium pyruvate, 100x diluted antibiotic-antimycotic and 10% complement-inactivated (56°C for 30 minutes) fetal bovine serum (FBS). A tumor model was prepared by injecting 2×105 CT-26 tumor cells suspended in 100 μl phosphate buffered saline (PBS) subcutaneously into the right hindlimb of BALB/cByJNarl mice. The tumor was allowed to grow for 9–11 days to reach a maximum diameter of 8–11 mm before FUS treatment.
Setup of Sonogram-guided MB-FUS exposure
Animals were anesthetized with isofluorane (2.5-3% volume with oxygen). The animal was placed on the acrylic holder and the skin flanking the tumor was fastened and fixed by stainless clips. The top of the tumor was attached to the bottom of the filled water tank which had a 50×50-mm2 opening. This opening was sealed with an acoustic-energy permeable membrane and a 3-mm-thick gelatin pad to insure perfect coupling with no intervening gas. FUS exposure was delivered at 5 and 30 W of electrical power, equivalent to measured acoustic negative-peak pressures of 0.6 and 1.4 MPa, respectively. Before focused ultrasound exposure, a 0.1 mL/kg bolus of SonoVue MBs (Sonovue, Bracco Diagnostics Inc., Milan, Italy) mixed with 0.2 mL of saline was injected intravenously (IV), followed by flushing with 0.2 mL heparin. Immediately after MB bolus injection (typically within 10 seconds), burst-mode FUS energy was delivered to the animal (burst length = 100 ms, pulse repetitive frequency = 1 Hz, sonication duration = 20s; parameters were selected based on our previous experience in increasing brain tissue vascular permeability ). Multiple sonications were carried out to completely cover the tumor. Animals typically underwent 9 to 12 sonications to allow coverage of the entire tumor region (range of total exposure time 180s to 240s). Since the focal dimension was measured as approximately 3 mm along the radial direction, the spacing between individual adjacent focal positions was set at 3 mm. A total of 280 animals were used in this study (Additional file 1: Table S1). Twelve animals were used to test tumor vascular permeability by injecting FITC-dextrans; 99 animals were assigned to observation of tumor progression; and 45, 30 and 71 animals were sacrificed 1, 3, and 18 days after MB-FUS exposure, respectively, to evaluate TIL infiltration. An additional 23 animals were used to confirm histological changes.
To rule out temperature elevation as a confounding factor, temperature measurements were conducted in a tissue-mimicking phantom using the same FUS exposure energy. A single-point thermocouple (T-type, diameter=0.05 mm, thin-epoxy coating and bare tip) was inserted into the phantom so that the tip colocalized with the focal spot. The thermocouple was connected to a thermometer system (TC-2190, National Instruments, Austin, TX, USA) for temperature acquisition. Temperature measurements were performed with a sampling frequency of 1 Hz using a PC connected to a GPIB interface.
Isolation of TILs
Tumors from day 1, 3 and 18 tumor-bearing mice were chopped into small pieces using a razor blade and 1g of tumor was incubated with 10 ml collagenase type IV (1mg/ml; GIBCO, CA, USA) in PBS buffer on a shaking incubator (100 rpm) at 37°C for 30 min. Cells were passed through nylon mesh, centrifuged at 1800 rpm for 3 minutes, and washed with RPMI1640 medium. Cell pellets were re-suspended in 8 ml RPMI1640 medium and layered over 4 ml Ficoll (Pharmacia, Peapack, NJ) in a 15-ml centrifuge tube. After centrifugation at 2000 rpm for 20 minutes with the deceleration speed set at 2, the single-cell suspension was separated from the Ficoll, and the leukocytes were recovered from the interface.
Antibodies and flow cytometry
Anti-CD4-PE, anti-CD45-PE, anti-Foxp3-APC, anti-CD8-APC, anti-FceRIa-APC, anti-CD117-FITC and anti-CD45-FITC antibodies were used for intracellular staining. TILs were washed twice with Hank’s balanced salt solution (HBSS), then fixed and permeabilized in Fix/Perm buffer according to the manufacturer’s instructions for 30 min. Cells were washed twice with permeabilization buffer and then incubated with appropriate antibodies at 4°C for 30 min in the dark. Unbound antibodies were removed by washing twice with permeabilization buffer. Flow cytometry analyses were performed on a three-color fluorescence FACScalibur cytometer using CellQuest software (Becton-Dickinson, CA, USA).
To confirm FUS-induced blood vessel permeability enhancement, FITC-labeled dextran (60 kDa; 500 μL, 0.5 mg/mL; Santa Cruz Biotechnology, USA) was injected IV. Animals were sacrificed 2 hours after FUS treatment. Paraformaldehyde-fixed and paraffin-embedded tumors were used to prepare 10 μm-thick sections for fluorescence observation. Adjacent sections were stained with hematoxylin-eosin (HE) to observe histological changes after MB-FUS exposure. Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick end labeling (TUNEL) was conducted to detect apoptotic DNA damage using the Apo-Brdu-IHC in situ DNA fragmentation assay kit (BioVision, Mountain View, CA). Immunohistochemical (IHC) staining with anti-heat-shock-protein 60 (hsp60) antibody (dilution 1:200, Cat. No. SC-376261, Santa Cruz Biotechlogy, Santa Cruz, CA, USA) was also performed to investigate cell-damage- or stress-induced heat-shock-protein regulation. Animals were sacrificed 3 days after MB-FUS exposure. Ten micrometer sections from paraformaldehyde-fixed, praffin-embedded tumors were prepared for TUNEL and hsp60 IHC staining.
Statistical analysis and tumor volume measurement
Flow-cytometric data were displayed as means ± standard deviations. The Mann–Whitney U test was used for statistical analysis of differences between groups. Calculations were performed with PRISM (version 5.00; GraphPad Software). Differences were recognized as statistically significant at p < 0.05.
Tumor volume was assessed primarily by vernier caliper. Tumor volume was calculated as LxW2x0.52, where L was the longest diameter and W was the diameter perpendicular to L. Tumor volume was measured every third day after treatment, ending at 25 days post tumor implantation. To verify the accuracy of caliper-measured volume, some animals were subjected to magnetic resonance imaging (MRI) to acquire high-resolution images of tumor anatomy (field strength = 3 Tesla, Trio with Tim, Siemens, Erlangen, Germany). Tumor volume was quantified by analyzing T2-weighted images with the following parameters: TR/ TE = 3490 ms/ 98 ms, matrix size= 144 × 256, FOV = 47 × 83 mm, slice thickness = 1 mm. The MRI-based tumor measurements were found to be comparable to the caliper-based estimates (data not shown).
Sonogram-guided Microbubble-enhanced FUS exposure induces local enhancement of microvascular permeability within a tumor
Microbubble-enhanced FUS exposure is associated with an increase in host antitumor immune response
The tumor growth ratio was defined as the ratio of the tumor volumes of the 2nd and 1st time points, and was calculated for each two consecutive time points (Figure 6B). We noted that the most significant inhibition of tumor growth progression occurred within the first three days; The tumor growth ratio decreased from 2.3 to 1.9 and 1.74, respectively, for 0.6 and 1.4-MPa MB-FUS exposure (Figure 6B). No reduction in the tumor growth ratio was observed for 0.6 or 1.4-MPa FUS without MBs. These data suggested that MB-FUS-exposure resulted in an antitumor effect mainly within the initial 72 hours after treatment.
Microbubble-enhanced FUS exposure provides local modulation of the immune environment
One possible underlying mechanism to explain the changes in tumor permeability or microenvironment and TIL infiltration in response to MB-FUS is that MB-FUS exposure may trigger the production of heat-shock protein (hsp) or other immunomodulatory factors (so-called danger signals) which could in turn trigger TIL infiltration. Previous studies demonstrated that hsp is not only induced by heat, but can also be triggered by mechanical stress [33, 34]. Kruse et al. demonstrated that hsp70 overexpression is sometimes observed within a similar pressure range (intensity = 53 W/cm2) and a short duration (1s) of ultrasound exposure without temperature elevation , similar to induction caused by heat from HIFU exposure . We therefore evaluated hsp60 expression and found that hsp60 indeed increased in regions of FUS exposure compared to control tumor regions, suggesting that induction of hsp overexpression may be involved in triggering of the immune response by MB-FUS (Additional file 1: Figure S1).
Besides expression of hsp or release of other danger signals, vascular disruption caused by FUS exposure may also be directly or indirectly involved in the observed tumor suppression. Previous reports showed that direct damage of the tumor endothelium will initiate vascular collapse, shut down tumor blood flow, and induce ischemic neoplastic cell death [36, 37]. Strategies aimed at causing such vascular disruption include targeted gene therapy, antibodies to neovascular antigens, fusion proteins directed against specific endothelial cell receptors, cytokine induction, or agents that selectively target the cytoskeleton of proliferating endothelial cells [38, 39]. Previous evidence demonstrated that CW-HIFU exposure can disrupt tumor blood vessels in liver cancer patients due to acoustic cavitation . It is therefore possible that microvascular disruption could explain or contribute to the anticancer effect caused by our MB-facilitated FUS exposure.
Conventional CD4+T cells (CD4+Foxp3-T or non-Treg cells) are intriguing since they appear to play an important role in the development of mature CTLs  and long-lived functional memory CD8+T cells . In a murine chronic viral infection model, CD4+T cell transfer was shown to effectively reverse the effects of exhausted CD8+T cells [43, 44]. In our study MB-FUS exposure facilitated a response of mostly conventional CD4+T cells with a moderate response by CD8+T cells, and no response by Treg cells, consistent with an antitumor function of conventional CD4+T cells as borne out by tumor growth inhibition. The gradual increase in CD8+T cells at days 3 and 18 might be explained by assistance from the initial surge of conventional CD4+T cells.
Sato et al. reported that among ovarian cancer patients, those with a high CD8+/CD4+ ratio had significantly higher survival, whereas Tregs were associated with an unfavorable prognosis . They concluded that CD8+ TILs and high CD8+/Treg ratios are associated with a favorable prognosis. However, others have reported that changes in the CD8+/CD4+ ratio were associated with a trend towards worse patient prognosis . These differences may be ascribed to CD4+ cells containing both Treg and non-Treg cells that have opposite effects on CD8+ cells. In our study, inhibition of tumor growth by MB-FUS was accompanied by a significant increase in the percentage of non-Treg CD4+ and CD8+T cells and an increase in the ratio of CD8+/Treg, suggesting that changes in these cell populations within the tumor microenvironment indeed affected tumor growth.
The role of mast cells in tumor development is more complicated since they can both help and inhibit tumor development . Mast cells can serve as promoters of the inflammatory response  but can also increase the invasion of tumor cells by degrading the extracellular matrix and promoting angiogenesis . Mast cells are capable of expanding  and recruiting Treg cells , but have also been shown to abolish the suppressive functions of Treg cells . The complicated roles of mast cells and the dual pattern of changes in mast cells in our study need to be further investigated to decipher their impact in the altered tumor microenvironment.
The immune-triggering effects of high-pressure CW-HIFU have been studied for nearly two decades . Indeed, the immune response triggered by CW-HIFU could potentially be just as effective for cancer treatment as the thermal-ablation of cancer cells [17, 19, 22, 54]. CW-HIFU thermal ablation of osteosarcoma, hepatocellular carcinoma, and renal cell carcinoma was found to be accompanied by a marked increase in CD4+ cells at the ablated tumor-tissue margins, but no significant changes in CD8+ or CD3+ cell populations . The thermal tumor-tissue destruction caused by CW-HIFU produces tumor debris antigens  that attract infiltration of numerous leukocytes at the margins of the coagulated tissues [19, 54], and the immune response is thus primarily mediated by cell debris and the accompanying inflammatory reaction.
More recently, mechanical pulsed-HIFU tumor-cell destruction has been shown to elicit an antitumor immune response that is similar to that of thermal-ablation CW-HIFU . Hu et al. demonstrated that in this case increased release of endogenous ATP and hsp60 triggers secretion of interleukin-12 by DCs and TNF-α by macrophages . CTLs and IFN-γ-secreting cells are also elevated after treatment . In contrast to CW-HIFU or pulsed-HIFU that triggers an immune response due to cell death following thermal ablation or mechanical destruction, we showed that MB-enhanced 1.4-MPa focused ultrasound may boost the antitumor immunological response by increasing the permeability of the tumor microenvironment, in the absence of extensive cell damage.
Our data revealed the potential key role played by MBs in triggering an immune response with low-pressure FUS. Weak-pressure ultrasound exposure by itself is known to have a very limited capacity to activate an immunological response . Even long exposure times of animals to CW low-pressure ultrasound (0.66 W/cm2; 7–60 minutes) did not affect cell viability and was associated with only a slight increase in apoptotic keratinocytes and dendritic cells without any changes in important cytokines such as IL-6 and TNF-α when the intensity was increased to 5 W/cm2. The mechanical index (MI) is a better indicator of cell destruction. An ultrasound intensity level of 0.66-5 W/cm2 translates to a MI of 0.68-1.9 . We used a similar MI in our study (MI = 0.8 and 1.98 for 0.6- and 1.4-MPa 0.5 MHz ultrasound FUS exposure), although we employed the burst-tone mode with individual site exposure, which is equivalent to a total exposure time of 2s (100 ms/s × 20s). Thus it is unlikely that our FUS exposure could have triggered an immune cell response through cellular damage of tumor cells in the absence of microbubbles.
In conclusion, compared to the thermal or mechanical destructive impact of HIFU exposure that results in APC-presenting and macrophage-recruiting immunological changes, permeability-enhancing MB-FUS exposure presents a new opportunity to facilitate alterations in a tolerogenic tumor microenvironment, possibly serving as an independent therapeutic route or an effective adjuvant for current first-line cancer treatment.
Despite our promising results, we note that tumor growth was inhibited mainly during the first three days after treatment, and that more work will need to be carried out in an animal model to optimize the immune response and maximize growth inhibition. In addition, the detailed mechanism of cancer growth inhibition as mediated by changes in the tumor microenvironment and immune cell populations needs to be elucidated by further studies. However, 1.4-MPa MB-enhanced FUS is already known to be safe in human subjects, which could potentially speed the development and introduction of this potential anticancer treatment modality.
In this study, we successfully demonstrated that low-pressure pulsed-mode MB-FUS exposure enhanced microvascular permeability within the tumor and boosted the antitumor immune response. We showed that alteration of the immune response after FUS exposure included the gradual increase of CD8+ CTL infiltration, a sudden surge of CD4+ non-Treg cell infiltration, and an initial increase followed by decrease of the percentage of mast cells. CD4+ Treg cell levels were unchanged. In addition, low-pressure, MB-enhanced FUS exposure significantly inhibited tumor growth, especially in the initial days following treatment.
This work was supported by the National Science Council, TAIWAN (NSC-100-2321-B-182-010 and NSC-100-2120-M-182A-001).
- Hill CR, ter Haar GR: Review article: high intensity focused ultrasound–potential for cancer treatment. Br J Radiol. 1995, 68: 1296-1303. 10.1259/0007-1285-68-816-1296.View ArticlePubMedGoogle Scholar
- Kennedy JE: High-intensity focused ultrasound in the treatment of solid tumours. Nat Rev Cancer. 2005, 5: 321-327. 10.1038/nrc1591.View ArticlePubMedGoogle Scholar
- Tempany CM, McDannold NJ, Hynynen K, Jolesz FA: Focused ultrasound surgery in oncology: overview and principles. Radiology. 2011, 259: 39-56. 10.1148/radiol.11100155.View ArticlePubMedPubMed CentralGoogle Scholar
- Tempany CM, Stewart EA, McDannold N, Quade BJ, Jolesz FA, Hynynen K: MR imaging-guided focused ultrasound surgery of uterine leiomyomas: a feasibility study. Radiology. 2003, 226: 897-905. 10.1148/radiol.2271020395.View ArticlePubMedGoogle Scholar
- Wu F, Wang ZB, Chen WZ, Zou JZ, Bai J, Zhu H, Li KQ, Jin CB, Xie FL, Su HB: Advanced hepatocellular carcinoma: treatment with high-intensity focused ultrasound ablation combined with transcatheter arterial embolization. Radiology. 2005, 235: 659-667. 10.1148/radiol.2352030916.View ArticlePubMedGoogle Scholar
- Wu F, Wang ZB, Zhu H, Chen WZ, Zou JZ, Bai J, Li KQ, Jin CB, Xie FL, Su HB: Feasibility of US-guided high-intensity focused ultrasound treatment in patients with advanced pancreatic cancer: initial experience. Radiology. 2005, 236: 1034-1040. 10.1148/radiol.2362041105.View ArticlePubMedGoogle Scholar
- McDannold N, Tempany CM, Fennessy FM, So MJ, Rybicki FJ, Stewart EA, Jolesz FA, Hynynen K: Uterine leiomyomas: MR imaging-based thermometry and thermal dosimetry during focused ultrasound thermal ablation. Radiology. 2006, 240: 263-272. 10.1148/radiol.2401050717.View ArticlePubMedPubMed CentralGoogle Scholar
- Catane R, Beck A, Inbar Y, Rabin T, Shabshin N, Hengst S, Pfeffer RM, Hanannel A, Dogadkin O, Liberman B, Kopelman D: MR-guided focused ultrasound surgery (MRgFUS) for the palliation of pain in patients with bone metastases–preliminary clinical experience. Ann Oncol. 2007, 18: 163-167.View ArticlePubMedGoogle Scholar
- Gianfelice D, Gupta C, Kucharczyk W, Bret P, Havill D, Clemons M: Palliative treatment of painful bone metastases with MR imaging–guided focused ultrasound. Radiology. 2008, 249: 355-363. 10.1148/radiol.2491071523.View ArticlePubMedGoogle Scholar
- McDannold N, Clement G, Black P, Jolesz F, Hynynen K: Transcranial MRI-guided focused ultrasound surgery of brain tumors: Initial findings in three patients. Neurosurgery. 2010, 66: 323-332. 10.1227/01.NEU.0000360379.95800.2F.View ArticlePubMedPubMed CentralGoogle Scholar
- Ram Z, Cohen ZR, Harnof S, Tal S, Faibel M, Nass D, Maier SE, Hadani M, Mardor Y: Magnetic resonance imaging-guided, high-intensity focused ultrasound for brain tumor therapy. Neurosurgery. 2006, 59: 949-955. discussion 955–946.PubMedGoogle Scholar
- Hynynen K, Pomeroy O, Smith DN, Huber PE, McDannold NJ, Kettenbach J, Baum J, Singer S, Jolesz FA: MR imaging-guided focused ultrasound surgery of fibroadenomas in the breast: a feasibility study. Radiology. 2001, 219: 176-185.View ArticlePubMedGoogle Scholar
- Wu F, Wang ZB, Zhu H, Chen WZ, Zou JZ, Bai J, Li KQ, Jin CB, Xie FL, Su HB: Extracorporeal high intensity focused ultrasound treatment for patients with breast cancer. Breast Cancer Res Treat. 2005, 92: 51-60. 10.1007/s10549-004-5778-7.View ArticlePubMedGoogle Scholar
- Rewcastle JC: High intensity focused ultrasound for prostate cancer: a review of the scientific foundation, technology and clinical outcomes. Technol Cancer Res Treat. 2006, 5: 619-625.View ArticlePubMedGoogle Scholar
- Li CX, Xu GL, Jiang ZY, Li JJ, Luo GY, Shan HB, Zhang R, Li Y: Analysis of clinical effect of high-intensity focused ultrasound on liver cancer. World J Gastroenterol. 2004, 10: 2201-2204.PubMedPubMed CentralGoogle Scholar
- Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME: Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008, 8: 299-308. 10.1038/nrc2355.View ArticlePubMedPubMed CentralGoogle Scholar
- Wu F, Wang ZB, Lu P, Xu ZL, Chen WZ, Zhu H, Jin CB: Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation. Ultrasound Med Biol. 2004, 30: 1217-1222. 10.1016/j.ultrasmedbio.2004.08.003.View ArticlePubMedGoogle Scholar
- Deng J, Zhang Y, Feng J, Wu F: Dendritic cells loaded with ultrasound-ablated tumour induce in vivo specific antitumour immune responses. Ultrasound Med Biol. 2010, 36: 441-448. 10.1016/j.ultrasmedbio.2009.12.004.View ArticlePubMedGoogle Scholar
- Xu ZL, Zhu XQ, Lu P, Zhou Q, Zhang J, Wu F: Activation of tumor-infiltrating antigen presenting cells by high intensity focused ultrasound ablation of human breast cancer. Ultrasound Med Biol. 2009, 35: 50-57. 10.1016/j.ultrasmedbio.2008.08.005.View ArticlePubMedGoogle Scholar
- Hu Z, Yang XY, Liu Y, Sankin GN, Pua EC, Morse MA, Lyerly HK, Clay TM, Zhong P: Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. J Transl Med. 2007, 5: 34-10.1186/1479-5876-5-34.View ArticlePubMedPubMed CentralGoogle Scholar
- Liu F, Hu Z, Qiu L, Hui C, Li C, Zhong P, Zhang J: Boosting high-intensity focused ultrasound-induced anti-tumor immunity using a sparse-scan strategy that can more effectively promote dendritic cell maturation. J Transl Med. 2010, 8: 7-10.1186/1479-5876-8-7.View ArticlePubMedPubMed CentralGoogle Scholar
- Wu F, Wang ZB, Cao YD, Zhou Q, Zhang Y, Xu ZL, Zhu XQ: Expression of tumor antigens and heat-shock protein 70 in breast cancer cells after high-intensity focused ultrasound ablation. Ann Surg Oncol. 2007, 14: 1237-1242. 10.1245/s10434-006-9275-6.View ArticlePubMedGoogle Scholar
- Ferrara K, Pollard R, Borden M: Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery. Annu Rev Biomed Eng. 2007, 9: 415-447. 10.1146/annurev.bioeng.8.061505.095852.View ArticlePubMedGoogle Scholar
- Frenkel V, Li KC: Potential role of pulsed-high intensity focused ultrasound in gene therapy. Future Oncol. 2006, 2: 111-119. 10.2217/14796618.104.22.168.View ArticlePubMedGoogle Scholar
- Hwang JH, Brayman AA, Reidy MA, Matula TJ, Kimmey MB, Crum LA: Vascular effects induced by combined 1-MHz ultrasound and microbubble contrast agent treatments in vivo. Ultrasound Med Biol. 2005, 31: 553-564. 10.1016/j.ultrasmedbio.2004.12.014.View ArticlePubMedGoogle Scholar
- Vestweber D: Relevance of endothelial junctions in leukocyte extravasation and vascular permeability. Ann N Y Acad Sci. 2012, 1257: 184-192. 10.1111/j.1749-6632.2012.06558.x.View ArticlePubMedGoogle Scholar
- Liu HL, Wai YY, Chen WS, Chen JC, Hsu PH, Wu XY, Huang WC, Yen TC, Wang JJ: Hemorrhage detection during focused-ultrasound induced blood–brain-barrier opening by using susceptibility-weighted magnetic resonance imaging. Ultrasound Med Biol. 2008, 34: 598-606. 10.1016/j.ultrasmedbio.2008.01.011.View ArticlePubMedGoogle Scholar
- Bekeredjian R, Kroll RD, Fein E, Tinkov S, Coester C, Winter G, Katus HA, Kulaksiz H: Ultrasound targeted microbubble destruction increases capillary permeability in hepatomas. Ultrasound Med Biol. 2007, 33: 1592-1598. 10.1016/j.ultrasmedbio.2007.05.003.View ArticlePubMedGoogle Scholar
- Stieger SM, Caskey CF, Adamson RH, Qin S, Curry FR, Wisner ER, Ferrara KW: Enhancement of vascular permeability with low-frequency contrast-enhanced ultrasound in the chorioallantoic membrane model. Radiology. 2007, 243: 112-121. 10.1148/radiol.2431060167.View ArticlePubMedGoogle Scholar
- Hynynen K, McDannold N, Sheikov NA, Jolesz FA, Vykhodtseva N: Local and reversible blood–brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. NeuroImage. 2005, 24: 12-20. 10.1016/j.neuroimage.2004.06.046.View ArticlePubMedGoogle Scholar
- Fischer K, McDannold NJ, Zhang Y, Kardos M, Szabo A, Reusz GS, Jolesz FA: Renal ultrafiltration changes induced by focused US. Radiology. 2009, 253: 697-705. 10.1148/radiol.2532082100.View ArticlePubMedPubMed CentralGoogle Scholar
- Miller DL, Song J: Tumor growth reduction and DNA transfer by cavitation-enhanced high-intensity focused ultrasound in vivo. Ultrasound Med Biol. 2003, 29: 887-893. 10.1016/S0301-5629(03)00031-0.View ArticlePubMedGoogle Scholar
- Chano T, Tanaka M, Hukuda S, Saeki Y: Mechanical stress induces the expression of high molecular mass heat shock protein in human chondrocytic cell line CS-OKB. Osteoarthr Cartil. 2000, 8: 115-119. 10.1053/joca.1999.0279.View ArticlePubMedGoogle Scholar
- Xu Q, Schett G, Li C, Hu Y, Wick G: Mechanical stress-induced heat shock protein 70 expression in vascular smooth muscle cells is regulated by Rac and Ras small G proteins but not mitogen-activated protein kinases. Circ Res. 2000, 86: 1122-1128. 10.1161/01.RES.86.11.1122.View ArticlePubMedGoogle Scholar
- Kruse DE, Mackanos MA, O’Connell-Rodwell CE, Contag CH, Ferrara KW: Short-duration-focused ultrasound stimulation of Hsp70 expression in vivo. Phys Med Biol. 2008, 53: 3641-3660. 10.1088/0031-9155/53/13/017.View ArticlePubMedPubMed CentralGoogle Scholar
- Siemann DW, Shi W: Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys. 2004, 60: 1233-1240. 10.1016/j.ijrobp.2004.08.002.View ArticlePubMedGoogle Scholar
- Denekamp J: Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev. 1990, 9: 267-282. 10.1007/BF00046365.View ArticlePubMedGoogle Scholar
- Chaplin DJ, Hill SA: Selective induction of tumor ischemia: development of vascular targeting agents for cancer therapy. Curr Opin Investig Drugs. 2002, 3: 1381-1384.PubMedGoogle Scholar
- Thorpe PE: Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 2004, 10: 415-427. 10.1158/1078-0432.CCR-0642-03.View ArticlePubMedGoogle Scholar
- Wu F, Chen WZ, Bai J, Zou JZ, Wang ZL, Zhu H, Wang ZB: Tumor vessel destruction resulting from high-intensity focused ultrasound in patients with solid malignancies. Ultrasound Med Biol. 2002, 28: 535-542. 10.1016/S0301-5629(01)00515-4.View ArticlePubMedGoogle Scholar
- Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002, 298: 850-854. 10.1126/science.1076514.View ArticlePubMedPubMed CentralGoogle Scholar
- Bevan MJ: Helping the CD8(+) T-cell response. Nat Rev Immunol. 2004, 4: 595-602. 10.1038/nri1413.View ArticlePubMedGoogle Scholar
- Aubert RD, Kamphorst AO, Sarkar S, Vezys V, Ha SJ, Barber DL, Ye L, Sharpe AH, Freeman GJ, Ahmed R: Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proc Natl Acad Sci USA. 2011, 108: 21182-21187. 10.1073/pnas.1118450109.View ArticlePubMedPubMed CentralGoogle Scholar
- West EE, Youngblood B, Tan WG, Jin HT, Araki K, Alexe G, Konieczny BT, Calpe S, Freeman GJ, Terhorst C: Tight regulation of memory CD8(+) T cells limits their effectiveness during sustained high viral load. Immunity. 2011, 35: 285-298. 10.1016/j.immuni.2011.05.017.View ArticlePubMedPubMed CentralGoogle Scholar
- Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005, 102: 18538-18543. 10.1073/pnas.0509182102.View ArticlePubMedPubMed CentralGoogle Scholar
- Shah W, Yan X, Jing L, Zhou Y, Chen H, Wang Y: A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell Mol Immunol. 2011, 8: 59-66.View ArticlePubMedPubMed CentralGoogle Scholar
- Khazaie K, Blatner NR, Khan MW, Gounari F, Gounaris E, Dennis K, Bonertz A, Tsai FN, Strouch MJ, Cheon E: The significant role of mast cells in cancer. Cancer Metastasis Rev. 2011, 30: 45-60. 10.1007/s10555-011-9286-z.View ArticlePubMedGoogle Scholar
- Kalesnikoff J, Galli SJ: New developments in mast cell biology. Nat Immunol. 2008, 9: 1215-1223. 10.1038/ni.f.216.View ArticlePubMedPubMed CentralGoogle Scholar
- Maltby S, Khazaie K, McNagny KM: Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta. 2009, 1796: 19-26.PubMedPubMed CentralGoogle Scholar
- Kambayashi T, Allenspach EJ, Chang JT, Zou T, Shoag JE, Reiner SL, Caton AJ, Koretzky GA: Inducible MHC class II expression by mast cells supports effector and regulatory T cell activation. J Immunol. 2009, 182: 4686-4695. 10.4049/jimmunol.0803180.View ArticlePubMedPubMed CentralGoogle Scholar
- Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, Liu Y, Yuan Y, Unkeless J, Xiong H, Feng ZH: SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood. 2008, 112: 1269-1279. 10.1182/blood-2008-03-147033.View ArticlePubMedPubMed CentralGoogle Scholar
- Piconese S, Gri G, Tripodo C, Musio S, Gorzanelli A, Frossi B, Pedotti R, Pucillo CE, Colombo MP: Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. Blood. 2009, 114: 2639-2648. 10.1182/blood-2009-05-220004.View ArticlePubMedGoogle Scholar
- Rosberger DF, Coleman DJ, Silverman R, Woods S, Rondeau M, Cunningham-Rundles S: Immunomodulation in choroidal melanoma: reversal of inverted CD4/CD8 ratios following treatment with ultrasonic hyperthermia. Biotechnol Ther. 1994, 5: 59-68.PubMedGoogle Scholar
- Lu P, Zhu XQ, Xu ZL, Zhou Q, Zhang J, Wu F: Increased infiltration of activated tumor-infiltrating lymphocytes after high intensity focused ultrasound ablation of human breast cancer. Surgery. 2009, 145: 286-293. 10.1016/j.surg.2008.10.010.View ArticlePubMedGoogle Scholar
- Scarponi C, Nasorri F, Pavani F, Madonna S, Sestito R, Simonacci M, De Pita O, Cavani A, Albanesi C: Low-frequency low-intensity ultrasounds do not influence the survival and immune functions of cultured keratinocytes and dendritic cells. J Biomed Biotechnol. 2009, 2009: 193260-View ArticlePubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.